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Indications for Acute and Chronic Digitalis Administration
in Heart Failure
Mihai Gheorghiade, MD*

A

lthough digitalis glycosides were introduced for the treatment of cardiac disorders almost 200 years ago, doubt persists regarding the role of these inotropic agents in the treatment
of heart failure patients with a normal sinus rhythm. Cardiac
glycosides are undoubtedly highly effective in controlling the
ventricular response in the presence of atrial fibrilladon, and
thereby enhance cardiac performance. Past experimental and
clinical data have shown that various digitalis preparations improve ventricular function when the dmg is acutely administered
and indices of myocardial contractility are measured (1-3), However, a dissociation may exist between the effects of digitalis on
indices of ventricular contractility (systolic time intervals,
measurements of rate of rise of left ventricular pressure, or direct measurement of myocardial contractile force) and overall
cardiac pump performance, which is expressed as the relationship between left ventricular filling pressure and cardiac output. Although indices of contractility can be shown to increase
with acute administration of digitalis, significantly improved
pump performance does not always occur (4-7),
The clinical use of digitalis should be reexamined for several
reasons. Concerning the benefit of digitalis, the literature is
somewhat confusing because authors fail to distinguish acute
and chronic effects of the dmg. Scant information is available
demonstrating the relative effect of cardiac glycosides compared
to the combination of diuretics and vasodilators in the treatment
of heart failure. A troubling risk of toxicity remains because of
the nanow borderline between the therapeutic and toxic effects;
toxic manifestations of digitalis therapy still comprise some
of the most prevalent adverse drug reactions encountered in
clinical practice (8). Except for the use of digitalis in atrial
fibrillation, it is uncertain who benefits from digitalis. Cardiac
glycosides purportedly increase mortality when administered
soon after myocardial infarction (9,10). In patients initially
treated with diuretics to maintain dry body weight, no added
benefit from digitalis is observed (11). Newer inotropic drugs
and vasodilators have been shown to be effective in treating
heart failure patients and may be superior to digitalis (12),

Acute Use of Cardiac Glycosides
Digitalis in acute myocardial infarction
Although digitalis therapy in patients with acute myocardial
infarction has been employed since 1912 (13), controversy persists regarding tbe indications and use of digitalis in such patients. Investigation ofthe effects of digitalis on cardiac function
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in patients having congestive heart failure in both the acute and
convalescent phases of myocardial infarction yields conflicting
and inconsistent data (14,15).
If digitalis is administered to patients in sinus rhythm during
the acute phase of myocardial infarction with either absent or
mild clinical heart failure, little hemodynamic benefit can be expected (16,17). In contrast, digitalis therapy is of value in this
setting when atrial fibrillation is present; benefit is obtained by
control ofthe ventricular response to the tachyanhythmia. Digitalis might be of benefit when signs of heart failure are accompanied by an S3 gallop, significant cardiomegaly, and elevation
ofthe left ventricular end-diastolic pressure. However, even in
this setting, few studies in humans are available that suggest
a significant improvement in left ventricular performance with
digitalization (18). Fonesteret al (19), Lipp et al (20), and Goldstein et al (21) reported no occunence of hemodynamic improvement in their patients, whereas Hodges et al (22) reported
an improvement in only four of the ten patients studied. Rahimtoola et al (23) reported an improvement in left ventricular filling pressure without a significant change in cardiac index when
ouabain was administered within 48 hours of acute myocardial
infarction. In fact, rapid intravenous administration of digitalis may be detrimental, which is perhaps related to its acute
peripheral constrictor effect (16).
Infarct size—Varankov and associates (24) examined the
effect of acetylstrophanthidin on the rate of creatine phosphokinase (CK) efflux in 59 patients with acute myocardial infarction. They found an accelerated release of CK in the plasma
ofthese patients, with an evolving uncomplicated infarction,
and concluded that digitalis administration may have adversely
increased infarct size.
Arrhythmogenic effect—Whether patients with myocardial
infarction are more sensitive to the arrhythmogenic effects of
digitalis has not been definitively ascertained. Reicansky and
colleagues (25), using a double-blind randomized protocol,
found no difference in the incidence of rhythm disturbances between digoxin-treated and control padents with acute myocardial infarction. An increased susceptibility to anhythmias in the
presence of digitalis intoxication has been observed in experimental models following acute coronary ligation (26,27),
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Therapeutic approach—Patients in sinus rhythm with mild to
moderate heart failure (bibasilar rales, S3 gallop, and upper
zone pulmonary venous redistribution on chest roentgenogram)
secondary to acute myocardial infarction should receive diuretics alone or a combination of a diuretic and a vasodilator as the
first step in their management. Intravenous nitroglycerin or
nitropmsside appears to be highly effective in reducing the left
ventricular end-diastolic pressure and improving cardiac output
in such padents. The addition of digoxin to nitropmsside may
increase the cardiac output more than nitropmsside alone in patients with heart failure complicating myocardial infarction, but
it does not produce any further decrease in pulmonary capillary
wedge pressure (28).
Cardiogenic shock—The beneficial effects of digitalis have
been examined in the setting of cardiogenic shock, in which
marked hypotension is observed in association with an elevated
left ventricular filling pressure. The prognosis of patients with
cardiogenic shock appears to be unaltered following digitalis
administration (17). Clinical studies have reported that the dmg
does not appear to have any beneficial effect on left ventricular
function (29-31). Cohn and associates (29) demonstrated thatthe
early pressor effect of intravenously administered ouabain is
deleterious in patients with cardiogenic shock. Digitalis adds little when compared with the more potent inotropic agents such as
dobutamine (23).

Acute digitalization in patients with chronic heart failure
Not all padents with severe and chronic heart failure will
show an improvement in hemodynamics after the administration
of intravenous digitalis (32-35). Selzerand Malmborg (32) were
unable to predict which patients would respond to acute digitalis
administration (only 60% of their patients had a significant hemodynamic response). Yankopoulos et al (33) found that patients only in the New York Heart Association's functional class
111 or IV responded to intravenous ouabain, whereas in Cohn et
al's series (34) four of eight patients had hemodynamic deterioration which coincided with an increase in total systemic vascular resistance following intravenous digoxin. Ribner et al
(35), however, recently reported hemodynamic benefit with intravenous digoxin in all 11 patients with alcoholic or idiopathic
cardiomyopathy.
Therapeutic approach—Because patients admitted with an
exacerbation of chronic heart failure can be compensated with
diuretics, vasodilators, and intravenous inotropic agents (ie,
dobutamine and amrinone), digitalis should be reserved for only
those patients with heart failure complicated by atrial fibrillation
with a rapid ventricular response or those who have continuous
signs and symptoms of congestive heart failure despite optimal
doses of diuretics and vasodilators.

Chronic Use of Digitalis Glycosides
Digitalis in chronic heart failure
The value of long-term chronic oral digoxin therapy in
chronic heart failure patients is controversial. Benefits have not
been definitively demonstrated, and the risk of toxicity is always
present. We prospectively evaluated the clinical and hemo-
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Table 1
Maintenance Diuretic and Vasodilator Therapy
Before and After Digoxin Withdrawal
Diuretics/Vasodilators
Diuretics:
Furosemide
Hydrochlorothiazide
Vasodilators:
Hydralazine
Isosorbide dinitrate
Nitroglycerin ointment

No. of
Patients

Dose
Mean (Range)

12
8

55 mg (20 to 80 mg)
50 mg (25 to 100 mg)

2
13
3

93 mg (40 to 200 mg)
66 mg (40 to 120 mg)
2 in (2 to 4 in)

dynamic effects of digoxin discontinuation in patients with normal sinus rhythm and congestive heart failure (36). We sought to
determine changes not only in symptoms and physical findings
after discontinuation of the dmg but also in left ventricular function and exercise capacity. The major difference in our study design from that employed in previous studies was to maximize
therapy with diuretics and vasodilator dmgs before discontinuing digoxin.
Materials
The study group patient population was homogeneous in that
all had documented chronic heart failure secondary to coronary
artery disease. Twenty-four consecutive patients were prospectively studied. All 24 patients were men with a mean age of 60
years (range of 42 to 80 years). No patient had a history of atrial
tachyanhythmia. The indication for initiating long-term digoxin
therapy in the study cohort was the presence of clinical and/or
radiographic evidence of congestive heart failure. None of the
patients had congestive heart failure precipitated solely by recurring episodes of acute ischemia. Before discontinuing maintenance digoxin therapy, patients received the dmg for two to 180
months (average 39 months). Plasma digoxin levels were obtained six to eight hours after the last digoxin dose and ranged
from 0.8 to 2.2 ng/mL (1,2 ± 0.3 ng/mL, mean ± standard
deviation). The digoxin dosage was not adjusted to achieve a
therapeutic serum level, and only patients with a chronic
therapeutic level were entered into the study. Before digoxin
withdrawal, 21 patients (88%) were receiving diuretic and/or
vasodilator therapy for congestive heart failure (Table 1). A total
of 20 padents (83%) were receiving diuretics; 16 (66%) were
receiving vasodilators; 14 were receiving both diuretics and
vasodilators; and two patients were taking a long-acting nitrate
preparation and another vasodilator.
Concunent therapy for congestive heart failure or angina pectoris was not altered during the follow-up period except in two
patients in whom isosorbide dinitrate therapy was initiated because of symptoms consistent with worsening angina pectoris
and no change in the status of their heart failure.
Methods
Baseline studies were obtained while patients were still
receiving maintenance digoxin therapy and before dmg discontinuance. These studies consisted of the following: a complete
cardiovascular history, physical examination including measurement of body weight, a resting 12-lead electrocardiogram, a
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standard posteroanterior chest roentgenogram, a resting gated
cardiac blood pool scan, and a symptom-limited treadmill exercise test. Serial exercise testing as a method of assessment was
introduced midway into the study. The last 14 consecutive patients were studied in this manner.
Each patient was assigned a heart failure score based on
symptoms, signs, andfindingson chest roentgenography. Each
ofthe following was assigned one point when present: dyspnea
on exertion, paroxysmal noctural dyspnea, sinus tachycardia.
Table 2
Heart Rate, Blood Pressure, Body Weight,
Cardiothoracic Ratio, and Exercise Tolerance Before
and After Digoxin Discontinuation
Measurements
Heart rate (beats/min)
Blood pressure (mm Hg)
Systolic
Diastolic
Body weight (kg)
Cardiothoracic ratio
Exercise capacity* (min)

On Digoxin
75 ± 2

Off Digoxin
76 ± 2

122
73
78.3
0.53
6.1

125
72
78.2
0.53
7.2

±
±
±
±
±

4
2
2.7
O.OI
0.8

±
±
±
±
±

3
2
2.7
O.OI
0.9

'Exercise testing conducted in 14 consecutive patients. Values are expressed as mean :
standard error of the mean.

jugular venous distention, pulmonary end-inspiratory rales,
an S3 gallop, peripheral edema, a cardiothoracic ratio > 0.5,
radiographic interstitial edema, alveolar changes, pulmonary
venous hypertension, and pleural effusion. The score ranged
from zero, reflecting an absence of the 12 variables, to 12, representing the presence of each of the listedfindings.After completing a baseline evaluation, digoxin was discontinued in all
patients.
Statistical analysis
Values are expressed as mean ± standard enor of the mean.
Comparison between baseline and digoxin withdrawal studies
in individual patients was made using the paired t-test, and
comparison between groups was performed using analysis of
variance.
Results
One month after digoxin withdrawal no significant difference
was observed in resting heart rate; systolic, diastolic, or mean
blood pressure; body weight; or duration of symptom-limited
treadmill exercise (Table 2). Also, no difference was observed
in cardiac symptoms, physical findings, cardiothoracic ratio,
radiographic signs of pulmonary congestion, resting radio-
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Fig 1—Heart failure scores on and off digoxin. NS = not significant. Number of patients designated inside circles. (From
Gheorghiade M, Belier GA. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease
and congestive heart failure in sinus rhythm. Am J Cardiol
1983;51:1243-50. Reprinted with permission.)
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Fig 2—Cardiothoracic ratio measured on posteroanterior chest
roentgenogram on and two months off digoxin. NS = not significant. (From Gheorghiade M, Belier GA. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart
disease and congestive heart failure in sinus rhythm. Am J Cardiol 1983;51:1243-50. Reprinted with permission.)
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nuclide ejection fraction, or heart failure score compared with
the baseline evaluation gathered during chronic maintenance
digoxin therapy. Individual values for the heart failure score
before and after digoxin withdrawal are shown in Fig 1. The majority of the patients (67%) had cardiomegaly, as defined by a
cardiothoracic ratio greater than 0.5. One month after digoxin
discontinuance the cardiothoracic ratio was unchanged compared with the baseline measurements (Fig 2).
Left ventricular ejection fraction data are summarized in Fig
3. Both individual and mean values with and without digoxin
therapy are shown. Even in patients with an ejection fraction of
< 0.35, no significant differences were noted between the "on"
and "off" digoxin periods (Fig 4),

Discussion
Our study shows that cessation of oral maintenance digoxin
therapy for one month in a group of 24 men in sinus rhythm with
documented coronary artery disease and compensated congestive heart failure has little adverse effect. It must be emphasized that 88% of the patients were receiving diuretic and/or
vasodilator therapy concunent with digoxin discontinuation.
One ofthe potendal hazards of discontinuing digoxin in padents

with chronic congestive heart failure is the development of supraventricular tachyanhythmias. No patient in our study developed such rhythm disturbances.
The studies reported in the literature conceming the effect of
digitalis withdrawal in patients having heart failure are conflicting, primarily because of different patient populations and
whether maintenance diuretic and/or vasodilator therapy was
used. Investigators have found that digitalis therapy could be
discontinued without adverse effects in 50% to 100% of patients
with heart failure and sinus rhythm (36-47) (Table 3). Considerable differences exist between the studies regarding the age of
the patients (37,38), the etiology of heart failure (46), and semm
digoxin concentration (43). Populations studied ranged from
those without heart failure (42) through compensated (45) to
overt heart failure (44). In some studies the indications for digitalization were unclear (37,38,47). In the report by Dobbs et al
(40) the deterioration associated with digitalis withdrawal was
manifested by an increase in sodium and water retention. Decompensation might not have occuned if concomitant diuretic
and/or vasodilator therapy had been instituted and maximized
before digitalis discontinuation (36). McHaffie et al (11) could
not detect a symptomatic improvement when digitalis was given
to patients with heart failure who achieved a dry body weight
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Eig 3—Radionuclide left ventricular ejection fraction during chronic maintenance digoxin therapy and at one month
of digoxin discontinuance. NS = not significant. (From
Gheorghiade M, Belier GA. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease
and congestive heart failure in sinus rhythm. Am J Cardiol
1983;51:1243-50. Reprinted with permission.)
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ON
DIGOXIN
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Fig 4—Left ventricular ejection fraction on and off digoxin.
(From Gheorghiade M, Belier GA. Effects of discontinuing
maintenance digoxin therapy in patients with ischemic heart
disease and congestive heart failure in sinus rhythm. Am J Cardiol 1983;51:1243-50. Reprinted with permission.)
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Table 3
Clinical Effects of Digitalis Discontinuation in Patients
with Heart Failure and Sinus Rhythm

Authors
Slan-& Luchi (37)
Dall (38)
Fonrose et al (39)
Dobbs et al* (40)
Hull &
Mackintosh (41)
Krakauer &
Petersen (42)
Johnston &
McDevin (43)
Amold et al (44)
Fleg et al (45)
Lee et alt (46)
Griffiths et al (47)
Gheorghiade &
Belier (36)
Total

Year
1969
1970
1974
1977

Sample
Size
No.
11
80
31
46

Indications
for
Digitalization
U
U
CHF
CHF

Serum
Glycoside
Levels
No
No
Yes
Yes

Follow-up
Period
in Months
1
3
4
\.i

1977

18

CHF

Yes

1979

22

U

Yes

3 to 6

6(27)

1979
1980
1982
1982
1982

56
9
30
25
11

CHF
CHF
CHF
CHF
U

Yes
Yes
Yes
Yes
Ycs

3
1.5
6
1 to 5
1.5

8(14)
5(53)
0(0)
14(53)
1 (9)

1983

24

CHF

Yes

364
•Thirteen patients with atrial fibrillation were included inlo the trial.
tOnly patients with an S3 gallop had a clinical deterioration when digoxin was discontinued.
CHF = congestive heart failure, and U = unclear.

while on diuretic therapy. Furthermore, no significant hemodynamic benefit was noted in response to various digitalis preparations (48-50) in heart failure patients compensated with diuretics and/or vasodilators.
Therapeutic approach
The clinical benefit of chronic digitalis administration to patients with chronic heart failure and sinus rhythm who are already receiving diuretic and vasodilator agents is still unclear
Since digitalis has a narrow therapeutic-toxic ratio, it would
seem prudent to first treat these patients with diuretics and
vasodilators. WTien symptoms or clinical signs of heart failure,
including an S3 gallop (46), persist despite optimal diuretic and
vasodilator therapy, digitalis should be added. Digitalis therapy
is beneficial to patients who have any form of heart disease with
underlying atrial fibrillation or who are prone to episodes of supraventricular tachyanhythmias.
In patients already on chronic maintenance digitalis therapy,
who are well compensated and do not have a third heart sound or
history of atrial fibrilladon, an attempt should be made to discontinue the glycoside. Digitalis therapy should be avoided or
at least used with extreme caution in patients on quinidine therapy or in those with advanced age, cardiac amyloidosis, renal
failure, and severe pulmonary disease. Such patients have an
increased probability of toxic side-effects at any given dose. Because chronic digoxin therapy in patients with a recent myocardial infarction has little hemodynamic benefit, does not appear
to increase survival (51-53), and may actually be associated with
increased mortality and sudden death in certain populations
(9,10), it would be pmdent to restrict its use to only those patients with atrial fibrillation or those not responding to diuretics
and vasodilators.
In conclusion the following two points should be remembered. Acute digitalization is of litde or no value in controlling
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3

1

Clinical
Deterioration
No. (%)
0(0)
21 (26)
16(52)
16(35)
1(6)

0(0)
84 (24)

signs and symptoms in patients with acute or chronic heart
failure and should be reserved for those patients presenting in
atrial fibrillation with a rapid ventricular response. Maintenance
digitalis therapy should be used only in the presence of atrial
fibrillation or in patients whose signs and symptoms of heart
failure persist despite diuretic and vasodilator treatment and
who have a third heart sound.
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